Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+T Cells in Cutaneous Melanoma

Imagem de Miniatura
Arquivos
art_GIAVINA-BIANCHI_Increased_NYESO1_Expression_and_Reduced_Infiltrating_CD3T_Cells_2015.PDF (2.89 MB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2015
Editora
HINDAWI PUBLISHING CORPORATION
DOI
Indexadores
Scopus
Web of Science
Título da Revista
ISSN da Revista
Título do Volume
Autores
MUZIKANSKY, Alona
DUNCAN, Lyn M.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
Journal of Immunology Research, article ID 761378, 8p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
NY-ESO-1 is a cancer-testis antigen aberrantly expressed in melanomas, which may serve as a robust and specific target in immunotherapy. NY-ESO-1 antigen expression, tumor features, and the immune profile of tumor infiltrating lymphocytes were assessed in primary cutaneous melanoma. NY-ESO-1 protein was detected in 20% of invasive melanomas (16/79), rarely in in situ melanoma (1/10) and not in benign nevi (0/20). Marked intratumoral heterogeneity of NY-ESO-1 protein expression was observed. NY-ESO-1 expression was associated with increased primary tumor thickness (P = 0.007) and inversely correlated with superficial spreading melanoma (P < 0.02). NY-ESO-1 expression was also associated with reduced numbers and density of CD3+ tumor infiltrating lymphocytes (P = 0.017). When NY-ESO-1 protein was expressed, CD3+ T cells were less diffusely infiltrating the tumor and were more often arranged in small clusters (P = 0.010) or as isolated cells (P = 0.002) than in large clusters of more than five lymphocytes. No correlation of NY-ESO-1 expression with gender, age, tumor site, ulceration, lymph node sentinel status, or survival was observed. NY-ESO-1 expression in melanoma was associated with tumor progression, including increased tumor thickness, and with reduced tumor infiltrating lymphocytes.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/9690
Referências
  1. Andrade Valéria C C, 2008, Cancer Immun, V8, P2
  2. Armstrong B K, 1994, Cancer Surv, V19-20, P219
  3. Azimi F, 2012, J CLIN ONCOL, V30, P2678, DOI 10.1200/JCO.2011.37.8539
  4. Barrow C, 2006, CLIN CANCER RES, V12, P764, DOI 10.1158/1078-0432.CCR-05-1544
  5. Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0
  6. Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
  7. Chitale DA, 2005, MODERN PATHOL, V18, P119, DOI 10.1038/modpathol.3800232
  8. CLARK WH, 1989, J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893
  9. Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
  10. Davis ID, 2004, P NATL ACAD SCI USA, V101, P10697, DOI 10.1073/pnas.0403572101
  11. Duncan LM, 1998, J CUTAN PATHOL, V25, P11, DOI 10.1111/j.1600-0560.1998.tb01683.x
  12. Fox M. C., 2013, J AM ACAD DERMATOL, V68, p1 e1
  13. Fujita S, 2004, CLIN CANCER RES, V10, P6551, DOI 10.1158/1078-0432.CCR-04-0819
  14. Gnjatic S, 2002, P NATL ACAD SCI USA, V99, P11813, DOI 10.1073/pnas.142417699
  15. Gooden MJM, 2011, BRIT J CANCER, V105, P93, DOI 10.1038/bjc.2011.189
  16. Goydos JS, 2001, J SURG RES, V98, P76, DOI 10.1006/jsre.2001.6148
  17. Hemminger JA, 2013, MODERN PATHOL, V26, P282, DOI 10.1038/modpathol.2012.133
  18. Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
  19. Jager E, 2000, P NATL ACAD SCI USA, V97, P12198, DOI 10.1073/pnas.220413497
  20. Juretic A, 2003, LANCET ONCOL, V4, P104, DOI 10.1016/S1470-2045(03)00982-3
  21. KASPER CS, 1987, J AM ACAD DERMATOL, V16, P326, DOI 10.1016/S0190-9622(87)70044-9
  22. Keilholz U, 2005, J CLIN ONCOL, V23, P6747, DOI 10.1200/JCO.2005.03.202
  23. Konishi J, 2004, ONCOL REP, V11, P1063
  24. Kruger S, 2007, PATHOL ONCOL RES, V13, P91
  25. Kurashige T, 2001, CANCER RES, V61, P4671
  26. Linos E, 2009, J INVEST DERMATOL, V129, P1666, DOI 10.1038/jid.2008.423
  27. Luftl M, 2004, BRIT J DERMATOL, V151, P1213, DOI 10.1111/j.1365-2133.2004.06260.x
  28. Nakada Tetsuya, 2003, Cancer Immun, V3, P10
  29. Neuman HB, 2008, ANN SURG ONCOL, V15, P2034, DOI 10.1245/s10434-008-9915-0
  30. Oberthuer A, 2004, CLIN CANCER RES, V10, P4307, DOI 10.1158/1078-0432.CCR-03-0813
  31. Odunsi K, 2003, CANCER RES, V63, P6076
  32. Odunsi K, 2012, P NATL ACAD SCI USA, V109, P5797, DOI 10.1073/pnas.1117208109
  33. Pellacani G., 2008, J EUR ACAD DERMATOL, V22, P213
  34. Peng JR, 2005, CANCER LETT, V219, P223, DOI 10.1016/j.canlet.2004.07.028
  35. Piras F, 2005, CANCER, V104, P1246, DOI 10.1002/cncr.21283
  36. Piris A, 2012, DERMATOL CLIN, V30, P581, DOI 10.1016/j.det.2012.06.001
  37. Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
  38. Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001
  39. Scott A. M., 1997, LANCET, V349, pSII19
  40. Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
  41. Stratigos AJ, 2012, BRIT J DERMATOL, V167, P99, DOI 10.1111/j.1365-2133.2012.11092.x
  42. Svobodova S, 2011, EUR J CANCER, V47, P460, DOI 10.1016/j.ejca.2010.09.042
  43. Thomas NE, 2013, J CLIN ONCOL, V31, P4252, DOI 10.1200/JCO.2013.51.3002
  44. van Houdt IS, 2008, INT J CANCER, V123, P609, DOI 10.1002/ijc.23543
  45. Vaughan HA, 2004, CLIN CANCER RES, V10, P8396, DOI 10.1158/1078-0432.CCR-04-0809
  46. Velazquez Elsa F, 2007, Cancer Immun, V7, P11
  47. Wang Yu, 2004, Cancer Immun, V4, P11
  48. Weide B, 2012, J CLIN ONCOL, V30, P1835, DOI 10.1200/JCO.2011.40.2271
  49. Yakirevich E, 2003, CLIN CANCER RES, V9, P6453

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/60
Carregar mais